Skylar is an associate editorial director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.
She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on LinkedIn.
Validity assessments revealed that 2 algorithms utilizing administrative claims data and electronic medical records were accurate at identifying moderate and severe events signaling acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.
Older adults with chronic obstructive pulmonary disease (COPD) identified factors likely to encourage or discourage patients from utilizing different technologies to track and improve physical activity.
A panel of health care professionals reviewed published literature to develop a recommendation guide to advise providers on best practices when considering vaccinations for children with atopic dermatitis (AD) on dupilumab.
A study evaluating independent risk factors for invasive pulmonary aspergillosis (IPA) in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) validated a potential model that could help providers diagnose IPA earlier.
Investigators quelled concerns regarding whether patients with chronic obstructive pulmonary disease (COPD) would be likely to use eHealth tools after finding that most had internet access and were regular users of information technology.
Three recent conferences yielded new data on which treatment therapies are providing substantial benefits to patients and which ones are demonstrating more lackluster results.
Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).
Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of or unresponsive to other enthesitis-improving medications.
Treatable traits associated with the decline in lung function and quality of life (QOL) in patients with chronic obstructive pulmonary disease (COPD) were detected in a longitudinal study, highlighting targets that physicians can address to better individualize COPD management.
A study examining how US biosimilar uptake has evolved found that biosimilars launched more recently have seen better uptake than biosimilars that have been on the market for a longer period.
Variances between sex and age were found among patients with chronic obstructive pulmonary disease (COPD) with a viral infection who visited the emergency department (ED) visit or were hospitalized, highlighting the role that these factors play.
Physical frailty affects a large proportion of patients with chronic obstructive pulmonary disease (COPD) and chronic respiratory failure and current tools for detection may be inadequate, according to a recent report.
Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product.
Abstracts from the ATS 2021 International Conference addressed patient decision-making frameworks for seeking care for chronic obstructive pulmonary disease (COPD) and tactics used to assist hospitals in implementing readmission reduction plans.
Abstracts from the ATS 2021 International Conference provided some insight into tactics that could improve the effectiveness of pulmonary rehabilitation programs in patients with chronic obstructive pulmonary disease (COPD).
Some recent oncology news includes research into factors impacting the well-being of childhood cancer survivors; whether COVID-19 accommodations will last post-pandemic; and a possible new therapy for patients with polycythemia vera.
Sandoz Canada launches its sixth biosimilar, an anticoagulant used to treat deep vein thrombosis, on the Canadian market.
A literature review sheds light on cancer risk factors and suboptimal screening levels that persist in the United States among certain racial, ethnic, and socioeconomic groups, despite a steady decline in cancer deaths and smoking prevalence.
Posters presented at the ATS 2021 International Conference noted some ways clinical characteristics associated with patients with chronic obstructive pulmonary disease (COPD) differ based on different demographics and smoking status.
After switching to 1 of 2 adalimumab biosimilars, patients with inflammatory bowel disease (IBD) experienced comparable clinical outcomes to the reference product after 6 months, according to a recent study.
In a review, investigators concluded that physicians should use pulmonary function tests in addition to standard spirometry evaluations to better ensure that patients are appropriately being diagnosed and treated for chronic obstructive pulmonary disease (COPD).
Hospitalized infants with the rare metabolic disorder maple syrup urine disease (MSUD), who are intolerant to oral or enteral administration of branched-chain amino acid-free formula, may benefit from an intravenous formulation.
A poster presentation highlighted the impact that payer preferences could have on biosimilar utilization and the potential savings that could be generated if payers decide to take advantage.
Attribution algorithms for patients with newly diagnosed cancer should account for cancer type and stage, among other characteristics, to ensure that attribution measurements are accurately calculated, investigators concluded.
Under the lawsuit, Alvotech alleges that AbbVie is unlawfully taking advantage of patent laws and claims courts to prevent biosimilar competition rivaling its blockbuster drug, Humira, from entering the US market.
The model that incorporated environmental and lifestyle data collected from a fitness tracker and a smartphone app was successful at predicting acute exacerbation of chronic obstructive pulmonary disease (AECOPD) 7 days in advance.
Specific factors, such as experience with technology and health literacy, were key drivers of whether a patient with chronic obstructive pulmonary disease (COPD) would benefit or be likely to use eHealth tools to improve self-management skills, investigators concluded.
Administrative claims data in oncology often lack sufficient information to conduct postmarketing comparison studies of biosimilars with their reference product, suggesting that other sources are needed to answer critical research questions.
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative.
